NASDAQ · MXCT
Healthcare · Medical - Devices
$1.29
Up+$0.07 (+5.74%)
Updated Sep 1, 2026, 10:19 AM
SID Score
4.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
MXCT closed at $1.29 after 21 trading sessions, up 20.56% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 31, 2026 | $1.19 | $1.315 | $1.19 | $1.29 | 777.28K |
| Aug 28, 2026 | $1.30 | $1.30 | $1.21 | $1.22 | 563.72K |
| Aug 27, 2026 | $1.31 | $1.325 | $1.28 | $1.28 | 360.77K |
| Aug 26, 2026 | $1.35 | $1.35 | $1.31 | $1.31 | 292.3K |
| Aug 25, 2026 | $1.38 | $1.39 | $1.34 | $1.35 | 310.49K |
| Aug 24, 2026 | $1.36 | $1.40 | $1.35 | $1.39 | 620.49K |
| Aug 21, 2026 | $1.40 | $1.40 | $1.355 | $1.38 | 435.91K |
| Aug 20, 2026 | $1.39 | $1.405 | $1.36 | $1.38 | 611.85K |
| Aug 19, 2026 | $1.29 | $1.40 | $1.2705 | $1.39 | 948.46K |
| Aug 18, 2026 | $1.30 | $1.31 | $1.26 | $1.27 | 443.7K |
| Aug 17, 2026 | $1.32 | $1.39 | $1.295 | $1.32 | 703.26K |
| Aug 14, 2026 | $1.39 | $1.407 | $1.27 | $1.32 | 1M |
| Aug 13, 2026 | $1.17 | $1.54 | $1.16 | $1.39 | 3.8M |
| Aug 12, 2026 | $1.36 | $1.36 | $1.22 | $1.27 | 1.96M |
| Aug 11, 2026 | $1.22 | $1.26 | $1.20 | $1.24 | 745.95K |
| Aug 10, 2026 | $1.17 | $1.225 | $1.16 | $1.21 | 925.56K |
| Aug 7, 2026 | $1.12 | $1.18 | $1.12 | $1.18 | 464.48K |
| Aug 6, 2026 | $1.08 | $1.14 | $1.08 | $1.11 | 861.65K |
| Aug 5, 2026 | $1.11 | $1.12 | $1.07 | $1.07 | 496.89K |
| Aug 4, 2026 | $1.07 | $1.13 | $1.07 | $1.11 | 319.76K |
| Aug 3, 2026 | $1.06 | $1.095 | $1.05 | $1.07 | 374.63K |
The latest Smart Investors Daily articles mentioning MXCT.
MXCT research
Company profile and research snapshot.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 25, 2026 | Craig-Hallum | Buy | — |
| Aug 11, 2025 | BTIG | Neutral | — |
| Aug 7, 2025 | William Blair | Market Perform | — |
| Mar 12, 2025 | Stifel | Buy | — |
| Apr 23, 2024 | Stephens & Co. | Overweight | — |
No generated briefing is available yet.
Benzinga · Aug 19, 2026
MaxCyte, Inc. (NASDAQ:MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today
SeekingAlpha · Aug 12, 2026
MaxCyte, Inc. (MXCT) Q2 2026 Earnings Call August 12, 2026 4:30 PM EDTCompany ParticipantsEric AbdillMaher Masoud - President, CEO & Executive...
Benzinga · Aug 12, 2026
MaxCyte (NASDAQ:MXCT) affirms FY2026 sales outlook from $30.000 million-$32.000 million to $30.000 million-$32.000 million vs $31.082 million estimate.
Benzinga · Aug 12, 2026
MaxCyte (NASDAQ:MXCT) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.09) by 11.11 percent. This is a 33.33 percent increase over losses of $(0.12) per share from the same
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning MXCT.
